Virax Holdings has agreed to acquire Pathway Oncology in a reverse takeover which will see the Australia-listed company gain control of a global licence for emerging anti-cancer technology.
Virax Holdings has agreed to acquire Pathway Oncology in a reverse takeover which will see the Australia-listed company gain control of a global licence for emerging anti-cancer technology.